Study on the safety and efficacy of autologous platelet-rich plasma (PRP) in treatment of female stress urinary incontinence - Study on the safety and efficacy of autologous platelet-rich plasma (PRP) in treatment of female stress urinary incontinence

Abe Hirokazu0 个研究点目标入组 40 人开始时间: 2023年10月16日最近更新: 2023年11月20日

适应症

试验速览

暂无简介。

•1. Stress urinary incontinence
•2. Female whose consent acquisition date is more than 20 years and less than 85 years
•3. Patients who can appropriately evaluate pain from start of screening to the end of observation
•4. Patients who have received sufficient explanation using ICF and understand the contents, and who have obtained written consent to participate in the study group based on their free will
•5. Patients who can follow the scedule established until the end of the examination period

•1. Patients who have a skin disease or infection at the administration site on the day of screening test or autologous platelet-rich plasma (PRP) administration, and who are at risk of infection due to injection
•2. Patients with a history or complication of malignancy within 5 years before obtaining consent
•3. Patients with more than 150 ml of residual urine
•4. Patients with platelet abnormalities
•5. Patients taking anticoagulants
•6. Patients with thrombosis
•7. Patients with hypofibrinogenemia
•8. Patients with hemodynamic instability
•9. Patients with sepsis
•10. Patient with anemia
•11. Patients with acute or chronic infections
•12. Patients with infectious diseases (HBV, HCV, HIV), other serious diseases
•13. Patients with chronic liver dysfunction
•14. Patients who have a history or complication of drug dependence or alcoholism
•15. Patients with mental illness such as depression, dementia, schizophenia and anxiety
•16. Presence of a metal implant or any other contraindication to magnetic resonance imaging (MRI)
•17. Patients iudged inappropriate by doctors

发起方

Abe Hirokazu